United States Steel Corporation (NYSE:X) down by 1.51%, Myriad Genetics Inc (NASDAQ:MYGN)
United States Steel Corporation (NYSE:X): In the trading session on Thursday, United States Steel Corporation (NYSE:X) lost 1.51%. The trading started at an opening price of $19.27, touched an intraday high of $19.33 before falling to $18.97 for the day. More than 6.98 million shares were traded over Thursday while the average volume was much lower and stood at 9.37 million, measured over 30 days.
The United States Steel Corporation (NYSE:X) shares’ bought/sold ratio is 1.20. This represents a positive $1,194,253 net cash flow into its stock. If you give more than a cursory glance at option trading, it reveals that a net total of 55,586 call contracts were traded. In addition to this put contracts to the tune of 27,189 contracts, yielded a put/call ratio of 0.49.
Currently, the company is trading over and above the 50-day moving average and below the 200-day moving average. United States Steel Corporation (NYSE:X) is an integrated steel producer. It manufactures tubular and flat-rolled products. Its major production operations are located in North America and Europe.
Myriad Genetics, Inc (NASDAQ:MYGN): In the Thursday trading session, Newmont Mining Corp (NYSE:NEM) down by 0.49%. The opening price was $30.92 which reached an intraday high of $30.99 before dropping down to $30.48 on Thursday. More than 0.93 million shares were traded over the day while the average volume was much lower and stood at 1.07 million. This was calculated over a period of 30 days.
On Thursday the rise in Myriad Genetics, Inc (NASDAQ:MYGN) continued to react after the company reported that there had been an increase in its first-quarter sales which had resulted in it raising its 2013 estimates as well. For the quarter ending 31 March, Myriad said there was a 20% increase in total diagnostic testing revenue and it touched $148.4 million. There was a 9% rise, to $115.4 million in its breast and ovarian cancer test, BRACAnalysis. The company reported higher revenue from its prostate cancer test, Prolaris which had received FDA clearance in 2012. In the 2013 financial year, the company expects earnings per share of $1.65- $1.67 on revenue of $595M- $600M.